A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3‐kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies.Ian W. Flinn, Albert S. Yu, Nina D. Wagner‐Johnston et al.|Journal of Clinical Oncology|2011Cited by 18
A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.Ian W. Flinn, Albert S. Yu, Marshall T. Schreeder et al.|Blood|2010Cited by 16